Asset profile

Sotatercept · Winrevair

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved — Hypertension

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Heart FailureNon-Small Cell Lung Cancer · Phase 2

How the evidence outlook works ↗

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2028 (5)
March 2028 (1)
Phase 2HypertensionNot yet recruiting
Est. primary completion 2028-03-31 · NCT07498803 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)
Phase 2Pulmonary Arterial HypertensionActive not recruiting
Est. primary completion 2028-06-16 · NCT06925750 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)
Phase 2Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2028-09-21 · NCT05587712 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)
Phase 2HypertensionNot yet recruiting
Est. primary completion 2028-10 · NCT07266519 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (1)
Phase 3Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2028-12-07 · NCT07218029 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
May 2029 (1)
Phase 2Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2029-05-24 · NCT07646860 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2035 (1)
August 2035 (1)
Phase 2HypertensionActive not recruiting
Est. primary completion 2035-08-10 · NCT06814145 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.